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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYHepatocyte transplantation has the potential to cure inherited liver diseases, but its application is impeded by a scarcity of donor livers.
Therefore, we explored whether transplantation of hepatocyte-like cells (iHeps) differentiated from human induced pluripotent stem
cells (iPSCs) could ameliorate inherited liver diseases. iPSCs reprogrammed from human skin fibroblasts were differentiated to iHeps,
which were transplanted into livers of uridinediphosphoglucuronate glucuronosyltransferase-1 (UGT1A1)-deficient Gunn rats, a model
of Crigler-Najjar syndrome 1 (CN1), where elevated unconjugated bilirubin causes brain injury and death. To promote iHep proliferation,
30% of the recipient liver was X-irradiated before transplantation, and hepatocyte growth factor was expressed. After transplantation,
UGT1A1+ iHep clusters constituted 2.5%–7.5% of the preconditioned liver lobe. A decline of serum bilirubin by 30%–60% and biliary
excretion of bilirubin glucuronides indicated that transplanted iHeps expressed UGT1A1 activity, a postnatal function of hepatocytes.
Therefore, iHeps warrant further exploration as a renewable source of hepatocytes for treating inherited liver diseases.INTRODUCTION
Stem cells offer enormous promise as a source of differenti-
ated cells for curing human diseases. Although liver trans-
plantation is curative for life-threatening metabolic liver
disorders (A˚berg et al., 2011), minimally invasive catheter
infusion of isolated hepatocytes into the liver can partially
correct metabolic liver diseases and can greatly reduce the
risk of fatal complications (Fox et al., 1998; Lysy et al.,
2008; Roy-Chowdhury et al., 2009; Fisher and Strom,
2006). Host conditioning regimens developed in our labo-
ratories (Guha et al., 2002) allow the expansion of
engrafted donor hepatocytes, leading to complete cures
of animal models of metabolic liver diseases. This host con-
ditioning strategy is now being tested in a clinical hepato-
cyte transplant trial (University of Pittsburgh, Institutional
Review Board [IRB] number PRO09040497).
Clinical application of hepatocyte transplantation has
been impeded by the scarcity of donor livers, which are
prioritized for organ transplantation. Pioneering studies
have shown that somatic cells can be reprogrammed
into induced pluripotent stem cells (iPSCs) that resemble
embryonic stem cells (ESCs) (Takahashi and Yamanaka,
2006; Yu et al., 2007). Recent successes in differentiating22 Stem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The AuthorsESCs and iPSCs into hepatocyte-like cells (iHeps) (Basma
et al., 2009; Lavon et al., 2004; Schwartz et al., 2005; Cai
et al., 2007; Duan et al., 2010; Si-Tayeb et al., 2010;
Song et al., 2009) has opened the possibility of using
iPSCs as a renewable source of human and, possibly, autol-
ogous hepatocytes.
Although iPSCs at various stages of differentiation have
been reported to engraft and improve the survival of mice
with severe toxic injury of the liver, neither the cause of
death from the toxic liver injury nor the correction of
any specific liver function by the engrafted cells has been
demonstrated (Liu et al., 2011). In this study, we examined
the efficacy of transplanting human iHep cells into Gunn
rats, a well characterized animal model of Crigler-Najjar
syndrome 1 (CN1) (Roy-Chowdhury et al., 1991, 1993).
CN1 is an autosomal recessive disorder in which genetic le-
sions of UGT1A1 cause life-long unconjugated hyperbiliru-
binemia because of a lack of uridinediphosphoglucuronate
glucuronosyltransferase 1A1-mediated bilirubin glucuroni-
dation by hepatocytes (Bosma et al., 1992). CN1 is lethal
unless treated with life-long daily phototherapy to reduce
bilirubin levels. Even with aggressive therapy, patients
remain at risk of bilirubin encephalopathy and death. Liver
transplantation is the only definitive therapy (Ozc¸ay et al.,
2009). Gunn rats are well characterized animal models of
CN1, with genetic and metabolic abnormalities similar to
CN1 patients.
In this study, we transplanted human iHeps into the
livers of Gunn rats. Proliferation of the transplanted cells
was induced by preconditioning a single liver lobe by he-
patic X-irradiation (HIR). HIR enhances the engraftment
of transplanted cells by transiently disrupting the sinusoi-
dal endothelial barrier. Additionally, reduction of the
mitotic capacity of the irradiated host hepatocytes provides
a competitive proliferative advantage to the engrafted cells
(Guha et al., 2002; Yamanouchi et al., 2009). Here, as with
patients, to increase the safety of HIR, we treated only one
liver lobe, representing 30% of the liver mass, to achieve
regional hepatic repopulation by the transplanted cells.RESULTS AND DISCUSSION
Characteristics of Adult Human Skin Fibroblast-
Derived iPSCs
iPSCs had a typical ESC-like morphology; expressed plurip-
otency markers (Figure S1A) at levels similar to those of the
H1 hESC line (WiCell); differentiated spontaneously to
cells of mesodermal, endodermal, and ectodermal origin
(Figure S1B); and gave rise to teratomas after injection in
severe combined immunodeficiency (SCID) mice (Fig-
ure S1C). iPSCs were diploid and contained 46 intact
chromosomes (Figure S1D), and RT-PCR showed that exog-
enous OCT-4, SOX2, KLF4, and c-MYC were silenced (data
not shown).Directed Differentiation of Human iPSCs and
Characteristics of iHeps
Undifferentiated iPSCs (Figure 1) expressed OCT-4 but
there was very little expression of hepatocyte-preferred
genes. After exposure to activin A and bFGF, OCT4 expres-
sion declined markedly, and the definitive endoderm
marker SOX17 and the nuclear factor FOXA2 were ex-
pressed in 70%–85% of cells. The fetal hepatocyte marker
a-fetoprotein (AFP) was expressed in 30%–50% of cells.
After culturing with HGF and DMSO, AFP expression
increased and human serum albumin (HSA) and CK18
were expressed. Following exposure to dexamethasone,
the morphology of a majority of the cells changed toward
that of primary human hepatocytes (Figures 2A–2C). Ama-
jority of these cells, termed iHeps, expressed HSA and cyto-
keratin 18, and less than half of the cells also expressed the
asialoglycoprotein receptor (ASGPR), a marker of mature
hepatocytes. AFP expression declined but was still seen in
1%–5% of cells (Figure 1). mRNA content measured by
qRT-PCR showed gene expression of transcription factors
that are important in hepatocyte development (e.g., HEXand PROX1) and maturation (e.g., HNF4a and C/EBPa)
and secreted proteins as well as cytosolic, ER, plasmamem-
brane, and peroxisomal proteins (Figure S2A). Confocalmi-
croscopy showed that ASGPR was distributed in both the
plasma membranes and the cytoplasm (Figures S2B–S2D),
whereas HSA was present in the cytoplasm (Figures S2E–
S2G). In this cell population, some albumin-negative cells
stained positive for SOX17, an early endodermal marker.
SOX17 staining was absent or very faint in albumin-ex-
pressing cells (Figures S2H–S2K). Flow cytometry showed
that 60%–90% of cells expressed HSA, whereas 28%–40%
of cells expressed ASGPR (Figure 2D). At all stages, differen-
tiation of iPSCs toward iHeps was similar to that seen
with human embryonic stem cells (hESCs) (Basma et al.,
2009). The iHeps exhibited hepatocyte-like characteristics,
including glycogen storage (by periodic acid Schiff
staining) (Figures 2E and 2F) and indocyanin green uptake
(Figure 2I). They also showed uptake of dioctadecylindocar-
bocyanine (DiI)-labeled low-density lipoproteins (Figures
2G and 2H). Western blot analysis of cell homogenates
confirmed that AFP appeared after iPSC exposure to activin
A plus bFGF and increased after exposure to HGF and
DMSO (Figure 2J). After exposure to dexamethasone, AFP
decreased markedly. AFP was undetectable in mature pri-
mary hepatocytes. A trace of HSA was found in iPSCs and
at the definitive endoderm stage (Figure 2J). HSA expres-
sion increased markedly after exposure to HGF plus
DMSO. After exposure to dexamethasone, the HSA content
reached 25% of that in freshly isolated primary human
hepatocytes (Figure 2L).
In contrast to AFP and HSA, significant levels of UGT1A1
appeared only after exposure to HGF plus DMSO. Develop-
mentally, UGT1A1 is expressed only with hepatocyte
maturation after birth. After exposure to dexamethasone,
the UGT1A1 content in iHeps increased markedly (Fig-
ure 2J), and UGT1A1 activity toward bilirubin was 18.8 ±
3.4 to 25.00 ± 4.6 pmole/min/mg protein (mean ± SD,
n = 4), which is 18%–22% of the mean UGT1A1
activity in isolated normal primary human hepatocytes
(Figure 2K).
As assessed by ELISA, the iHeps secreted the liver-specific
proteins HSA, transferrin, and a-1-antitrypsin (AAT) into
the culture medium at 33%, 46%, and 60% of the rate of
secretion by primary human hepatocytes under identical
conditions (Figures 2L–2N). iHeps secreted urea at approx-
imately half the rate of primary human hepatocytes (Fig-
ure 2O). Undifferentiated iPSCs did not secrete HSA, AAT,
transferrin, or urea (Figures 2K–2O).
Transplantation and Repopulation of Gunn Rat Livers
with iHeps
Gunn rats were transplanted with 2 3 106 viable HSA-
positive iHeps by intrasplenic injection as describedStem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The Authors 23
Figure 1. Expression of Cellular Marker
Proteins during Differentiation of Human
iPSCs
iPSCs were differentiated sequentially to
definitive endoderm, early hepatocytes,
and iHep cells as described in the text.
Immunofluorescence staining for human
OCT4, SOX17, FOXA2, AFP, HSA, CK18, and
ASGPR is shown. Scale bars, 100 mm. See
also Figure S1.previously (Zhou et al., 2012). Because the rats are im-
mune-competent, they were injected with tacrolimus
(2 mg/kg subcutaneously daily) starting 7 days before
transplantation to prevent xenograft rejection (Basma
et al., 2009). For comparison, two rats received 23 106 hu-
man hepatocytes isolated from the livers of fumaryl ace-
toacetate hydrolase-deficient, Rag2/, IL2-gc/ (FRG)
mice repopulated with human hepatocytes (purchased
from Yecuris). To induce the preferential proliferation of
transplanted cells, recipient rats received preparative HIR
(50 Gy) to the median liver lobe, constituting 30% of the
liver mass, on the day before transplantation and were
injected with an adenoviral vector expressing HGF (1012
particles) 24 hr after the transplant (Zhou et al., 2012).
Control rats (n = 4) received immunosuppression and
HIR but were injected with saline instead of iHeps or pri-
mary hepatocytes.24 Stem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The AuthorsImmunohistochemistry of liver sections of the precondi-
tioned median lobe using a human UGT1A group-specific
antibody showed clusters of human hepatocytes (Figures
3A and 3B) or iHep cells (Figures 3C–3E). A similar level
of repopulation with iHeps was found by staining for
HSA (Figures 2F and 2G). Image analysis using the ImageJ
program showed that, 4-6 months after transplantation,
the transplanted hepatocytes and iHeps comprised 17% ±
3.1% and 5.1% ± 2.6% (mean ± SD) of the hepatocyte
mass, respectively (Figure 3H). In non-irradiated liver lobes,
engrafted iHeps or primary human hepatocytes were seen
as single cells or in groups of two to three cells (data not
shown). Because hepatocytes engraft initially as single
cells, the formation of human cell clusters indicated the
proliferation of the engrafted cells in the preconditioned
lobe. As expected, no human UGT1A-positive cells were
found in control Gunn rat livers (data not shown). Liver
Figure 2. Characterization of the iHep Cells
The cells were differentiated in culture as described in Experimental Procedures.
(A–C) Phase contrast image of iPS cells, iHeps, and human primary hepatocytes, respectively. Scale bars, 100 mm.
(D) Flow cytometric analysis of HSA and ASGPR in iPSCs and iHeps. Scale bars, 100 mm.
(E) Periodic acid Schiff staining for glycogen content. Scale bars, 100 mm.
(F) Phase contrast image of (E).
(G) Uptake of DiI-LDL.
(H) Phase contrast image of (G).
(I) ICG uptake.
(J) Western blot for a-fetoprotein, human serum albumin, and UGT1A1: 1, undifferentiated human iPS; 2, definitive endoderm; 3, early
hepatocytes; 4, hepatocyte-like cells (after exposure to dexamethasone); 5, human liver primary hepatocytes; 6, human hepatoma cell line
HepG2.
(K) UGT1A1 activity toward bilirubin. The values are shown as percentage of the mean enzyme activity in homogenates of normal human
liver specimens. Means of four determinations ± SD are shown. HH, primary human hepatocytes. The values are shown per million cells
(means ± SD of data from four different iHep preparations).
(L–N) Secretion of human proteins into the media. After a fresh change of the serum-free culture medium, the cells were cultured for 24 hr,
the media were harvested, and specific protein concentrations were determined by ELISA. The values are shown per million cells (means ±
SD of data from four different iHep preparations).
(O) Urea secreted into the media. Cell culture and media harvesting was as in (L–N). The values are shown per million cells (means ± SD of
data from four different iHep preparations).
See also Figure S2.repopulation was also assessed by real-time genomic DNA
PCR for HLA-A54 (Bick et al., 2008) using primers that
did not yield any amplicons from the rat genomic DNA
template. As an internal control, we used the 36B4 gene
(O’Callaghan et al., 2008), which is amplifiedwith equal ef-
ficiency from rat and human genomic DNA (see details in
the Supplemental Experimental Procedures). By this mea-surement, human hepatocytes and iHeps constituted
18.2 ± 5.5 and 7.1 ± 4.8 (means ± SD) of the cells in the pre-
conditioned median lobe (Figure 3I) but were below the
detectable level in non-irradiated liver lobes. To assess pro-
tein secretion by the engrafted human hepatocytes and
iHeps, we measured HSA and human transferrin in recip-
ient Gunn rat sera by ELISA. Four to six months afterStem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The Authors 25
Figure 3. Repopulation of Gunn Rat
Livers with Transplanted Human iHep
Cells
(A–G) Four to six months after trans-
plantation, livers were harvested from Gunn
rats receiving iHeps or primary human he-
patocytes (PHH), and cryosections were
immunostained with a monoclonal anti-
body (WP1) that recognizes the carboxy-
terminal region of human UGT1A isoforms
(A–E) or an HSA-specific antibody (F and
G). Representative sections of HIR-pre-
conditioned median lobes are shown.
(A) recipient of PHH. Magnification, 43.
(B) Section of the same lobe as in (A).
Magnification, 103.
(C) An iHep recipient. Magnification, 43.
(D) The same lobe. Magnification, 103.
(E) The same lobe showing characteristic
cytoplasmic and nuclear envelope distri-
bution of UGT1A1. Magnification, 403.
(F) An iHep recipient, stained for HSA.
Magnification, 43.
(G) The same lobe. Magnification, 103.
(H) Morphometric determination of percent
repopulation by human UGT1A1-positive
engrafted iHep cells. Each liver lobe was cut
into six pieces, and cryosections from each
piece were immunostained for human
UGT1A1 as in (A). The proportion of hepa-
tocytes that were positively stained was
determined by counting ten fields repre-
senting 15,000 cells. Data from the median
lobes of four individual iHep recipient rats
(R1, R2, R3, and R4) and two PHH recipient
rats (PHH1 and PHH2) are shown.
(I) Quantification of liver repopulation by
iHeps by genomic DNA PCR. Genomic DNA
was extracted from homogenates of liver
lobes of the four recipient Gunn rats. The
repopulating human cells were quantified
by qPCR of the HLA-A54 gene as described
in the Supplemental Experimental Pro-
cedures. The highly conserved 36B4 gene
was amplified as an internal control for
both human and rat genes. Data are shown
from the median lobes of recipient Gunn
rats as in (F).
See also Figure S3.transplantation, mean HSA and human transferrin levels
in the four iHep recipients were 48–73 (60 ± 14) mg/ml
and 3.2–8.3 (5.75 ± 2.7) mg/ml, respectively (Figures S3A26 Stem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The Authorsand S3B). In recipients of primary human hepatocytes,
the levels were 232 ± 25 mg/ml and 27 ± 5 mg/ml, respec-
tively (Figures S3A and S3B). These levels were lower than
what might be predicted from the extent of liver repopula-
tion, which may reflect the limitations of xenografting in
immunocompetent recipients. Both proteins were unde-
tectable in pre-transplant Gunn rat sera and in sham-
treated controls.
To assess the correction of the metabolic abnormality in
Gunn rats, we determined hepatic UGT1A1 activity toward
bilirubin and serum bilirubin levels in transplant recipi-
ents. UGT1A1 activity was undetectable in livers of control
Gunn rats. In homogenates of preconditioned median
lobes of Gunn rats receiving human hepatocytes,
UGT1A1 activities were 3.2 ± 0.4 and 3.6 ± 0.6 nmol/g
wet weight/min1 (mean of three determinations ± SD).
UGT1A1 activities in iHep recipients were 0.52 ± 0.25
to 2.19 ± 0.38 nmol/g wet weight/min1 (mean ± SD,
n = 6), which was 1.5% to 5% of themean UGT1A1 activity
in homogenates of normal human liver (n = 4). In un-
treated control Gunn rats, serum bilirubin levels increased
with age (Figure 4A). In sham-treated controls, serum bili-
rubin increased to levels above those in untreated Gunn
rats for 4–8weeks, after which the levels equalized. In recip-
ients of human hepatocytes and iHeps, serum bilirubin
decreased over time by 70%–80% and 30%–61%, respec-
tively, from pre-transplant levels of 5–7 mg/dl (85–
119 mM) (n = 4, p < 0.01). The bilirubin levels were lower
(p < 0.01) than in age-matched controls (n = 6) 6weeks after
transplantation and at all time points thereafter (Figures 4A
and 4B).
To confirm the UGT1A1 activity of the engrafted iHeps
in vivo, we analyzed the bile from untreated control and
transplantedGunn rats by high-pressure liquid chromatog-
raphy (HPLC). Untreated Gunn rat bile contained only an
unconjugated bilirubin (ucb) peak and no bilirubin
glucuronides (Figure 4C). In contrast, bile from the iHep
recipients contained bilirubin diglucuronide (bdg) and
monoglucuronide (bmg), and the ucb peak was reduced
(Figure 4D). bdg and bmg are the predominant species in
congeneic normal Wistar-RHA rat bile, which contains
only a small amount of ucb (Figure 4E).
Although, in this study, we did not enrich iHeps for
ASGPR-expressing cells before transplantation to reduce
the risk of transplanting cells with tumor potential, at au-
topsy, recipient rats did not exhibit teratomas or any other
type of tumors despite significant proliferation of the en-
grafted cells after transplantation, suggesting the absence
of residual pluripotent cells after in vitro differentiation
of iPSCs.
Therefore, we demonstrated engraftment, proliferation,
and function of iHeps following transplantation by immu-
nohistochemical morphometry, qPCR of genomic DNA,
UGT1A1 activity in liver homogenates, reduction of serum
bilirubin, and excretion of bilirubin glucuronides in the
bile. The slightly lower values observed by immunostain-ing for human UGT1A1 could be because all engrafted
iHeps did not express UGT1A1. The function of engrafted
iHeps in vivo was also evidenced by the appearance of hu-
man proteins in the recipient rat serum. Importantly,
because UGT1A1 activity develops postnatally (Odell,
1967), the finding of UGT1A1 activity in the iHeps
in vitro and in vivo indicates that, at least in this respect,
the iHeps had matured beyond the level of fetal hepato-
cytes. Although our iHep cells did not exhibit all features
of mature hepatocytes, their engraftment and prolifera-
tion in the Gunn rat liver provided sufficient UGT1A1
activity to ameliorate jaundice. Human stem cell- or fibro-
blast-derived hepatocytes have been reported to engraft in
murine livers after severe liver injury (Liu et al., 2011).
Very recently, iHeps generated by a protocol similar to
that used in this study has been shown to engraft in the
livers of urinary plasminogen activator transgenic mice
and be infectable with hepatitis virus C in vivo (Carpentier
et al., 2014). In contrast to these studies, we provide defin-
itive evidence of the engraftment and function of iHeps by
reconstitution of a missing hepatocyte-specific enzyme ac-
tivity and significant amelioration of a metabolic liver
defect.
This study required several technical innovations. The
ability to limit the delivery of conditioning HIR of the me-
dian lobe permitted repopulation of a single liver lobe, leav-
ing the remaining liver unperturbed. Clinical studies using
conformal HIR indicate that partial liver irradiation causes
much less radiation-induced liver injury than whole-liver
irradiation, permitting the safe delivery of higher radiation
doses (Dawson and Ten Haken, 2005). Because the en-
grafted iHeps proliferated significantly only in the precon-
ditioned lobe, 5.1% ± 2.6% repopulation of the median
lobe was equivalent to about 1.7% ± 0.99% repopulation
of the entire liver. Nonetheless, this level of repopulation
was sufficient to significantly reduce the serum bilirubin
levels. Although serum bilirubin was not normalized, an
equivalent reduction in a clinical setting would be suffi-
cient to protect CN1 patients from developing brain injury
and could possibly circumvent the need for prolonged
phototherapy.
The ratio between HSA and human transferrin levels in
recipient rat sera was lower than that in the culture media
of iHeps. This could be because albumin is a negative acute-
phase reactant, and its synthesis could be downregulated in
the xenotransplanted cells.
Translating this approach to the clinic will require several
modifications. The iPSCs will need to be generated under
Good Manufacturing Practice conditions, using newer
methods of generating iPSCs without transgene integra-
tion (Yoshida and Yamanaka, 2011). Because of the small
size of the rodent recipients, we delivered regional HIR by
surgical exposure of the liver, but, for clinical application,Stem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The Authors 27
Figure 4. Metabolic Effect of Repopulation
(A) Serum bilirubin levels in the four Gunn rat iHeps (black lines) at the indicated time points after transplantation are shown as percent of
pretransplant levels (means ± SD of three determinations for each time point). Dashed black line, untreated age-matched controls
(means ± SD of 6 rats); dashed blue line, bilirubin levels in the sham-treated controls; red lines, bilirubin levels after transplantation of
primary human hepatocytes; Dotted line, upper limit of serum bilirubin levels in congeneic normal Wistar-RHA rats.
(B) Serum bilirubin levels (mean ± SD) at indicated intervals after transplantation. Open bar, untreated control (n = 6 rats); light blue,
sham-operated control (n = 4 rats); black, iHep transplant recipients (n = 4 rats); red, recipients of primary human hepatocytes (n = 2 rats).
*p < 0.02.
(C–E) High-pressure liquid chromatographic analysis of bilirubin species excreted in the bile of a control Gunn rat, a rat receiving iPSC-
derived hepatocytes, and a congeneic normal Wistar RHA rat. sf, solvent front. The absorbance unit scale in (E) is different from that in
(F and G).
See also Figure S3.regional HIR is delivered by conformal irradiation without
requiring surgery. Regional irradiation for hepatic repopu-
lation is now in a phase I trial. These readily achievable28 Stem Cell Reports j Vol. 5 j 22–30 j July 14, 2015 j ª2015 The Authorsadaptations should permit the safe application of this




Normal adult human skin fibroblasts were reprogrammed by retro-
viral transduction with pluripotency factors, OCT-4, SOX2, KLF4,
and c-MYC, as described previously (Takahashi and Yamanaka,
2006).
Differentiation of iPSCs to iHep Cells
The iPSCs were differentiated to iHeps as previously described for
human ESCs with somemodifications (Basma et al., 2009). Briefly,
embryoid bodieswere not produced, and iPSCs dispersed using dis-
pase were plated in monolayers. Definitive endoderm was gener-
ated by exposure to recombinant activin-A (R&D Systems) and
fibroblast growth factor 2 (Invitrogen). During the next 8 days,
the cells were exposed to HGF (R&D Systems) andDMSO, followed
by culturing for 3 days in dexamethasone-containing media
(Sigma). At each step, the expression of a series of markers was
determined by immunofluorescence staining (see Supplemental
Experimental Procedures and Figure 1).
Characterization of iHep Cells
To evaluate the hepatocyte-like characteristics of the iHep cells, we
determined the glycogen content and low-density lipoprotein
(LDL) and indocyanine green (ICG) uptake by the cells. We also
determined the HSA, AFP, and UGT1A1 content; UGT1A1 activity
toward bilirubin; as well as secretion of HSA and AAT in the media
(see details in the Supplemental Experimental Procedures). For
comparison, control primary hepatocytes were isolated from an
explanted liver during liver transplantation in a patient withmeta-
bolic liver disease.
Statistical Analysis
Serum bilirubin levels in individual rats were determined in tripli-
cate and expressed as percent of pre-transplant values. Data at each
time point were compared with those in the control group at the
same time point using Student’s unpaired two-tailed t test. The
number of mice in the control group is represented by n.
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